PhAST Diagnostics

Executive Summary

PhAST Diagnostics is a biotechnology company tackling the global crisis of antibiotic resistance through an AI-driven platform for rapid infectious disease diagnostics. The company's cloud-based system leverages single-cell imaging and computer vision to analyze patient samples in real time, providing clinicians with actionable insights to prescribe the most effective antibiotics quickly. This approach aims to reduce the misuse of broad-spectrum antibiotics, slow the emergence of resistant pathogens, and improve patient outcomes. By integrating into hospital workflows and supporting pharmaceutical drug development, PhAST offers a triple benefit: clinical decision support, operational efficiency, and accelerated R&D.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Diagnostic Platform60% success
• Q4 2026Strategic Partnership with Major Hospital Network70% success
• Q2 2026Series A Funding Round75% success